Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae - PubMed (original) (raw)

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae

L Martínez-Martínez et al. Antimicrob Agents Chemother. 1999 Jul.

Abstract

Two clinical isolates of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae were noted to be less susceptible than expected to imipenem. Both were missing outer membrane proteins that serve as channels for antibiotic entry. The role of beta-lactamase in resistance was investigated by eliminating the original ESBL and introducing plasmids encoding various ESBLs and AmpC beta-lactamase types, by studying the effect of an increased inoculum, and by evaluating interactions with beta-lactamase inhibitors. The contribution of porin deficiency was investigated by restoring a functional ompK36 gene on a plasmid. Plasmids encoding AmpC-type beta-lactamases provided resistance to imipenem (up to 64 microg/ml) and meropenem (up to 16 microg/ml) in strains deficient in porins. Carbapenem resistance showed little inoculum effect, was not affected by clavulanate but was blocked by BRL 42715, and was diminished if OmpK36 porin was restored. Plasmids encoding TEM- and SHV-type ESBLs conferred resistance to cefepime and cefpirome, as well as to earlier oxyimino-beta-lactams. This resistance was magnified with an increased inoculum, was blocked by clavulanate, and was also lowered by OmpK36 porin restoration. In addition, SHV-2 beta-lactamase had a small effect on carbapenem resistance (imipenem MIC, 4 microg/ml, increasing to 16 microg/ml with a higher inoculum) when porins were absent. In K. pneumoniae porin loss can thus augment resistance provided either by TEM- or SHV-type ESBLs or by plasmid-mediated AmpC enzymes to include the latest oxyimino-beta-lactams and carbapenems.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Albertí S, Rodríguez-Quiñones F, Schirmer T, Rummel G, Tomás J M, Rosenbusch J P, Benedí V J. A porin from Klebsiella pneumoniae: sequence homology, three-dimensional structure, and complement binding. Infect Immun. 1995;63:903–910. - PMC - PubMed
    1. Bauernfeind A, Hörl G. Novel R-factor borne β-lactamase of Escherichia coli conferring resistance to cephalosporins. Infection. 1987;15:257–259. - PubMed
    1. Bradford P A, Urban C, Mariano N, Projan S J, Rahal J J, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother. 1997;41:563–569. - PMC - PubMed
    1. Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum β-lactamases. J Antimicrob Chemother. 1989;24(Suppl. A):133–141. - PubMed
    1. Chow J W, Shlaes D M. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J Antimicrob Chemother. 1991;28:499–504. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources